US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 21:14:14 Source:opinionsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Cruise worker 'murders newborn son on board ship': Shocked co
Next:Amtrak train hits pickup truck in upstate New York, 3 dead including child
You may also like
- Nuggets blow 20
- Apps simplify expense steps for foreign users
- Traditional Ethnic Culture Enjoys Modern Glory on School Campuses
- Xinhua Headlines: China Speeds up Post
- Bella Hadid goes braless in a thigh
- China Beats Japan to Retain Asiad Women's Volleyball Title
- Nursing Home in E China's Hangzhou Recruits Young People to Accompany Elderly People
- Women's Wellness, Beauty Market Glowing Brightly
- French sports minister calls for sanctions after Monaco player tapes over anti